Text Size

The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

This study has been completed.
Sponsor:
Information provided by:
China-Japan Friendship Hospital
ClinicalTrials.gov Identifier:
NCT01342614
First received: April 26, 2011
Last updated: May 11, 2011
Last verified: November 2005
History of Changes
  Purpose

The objective of this study is to investigate the effect of metformin on the correlation between hyperinsulinemia and hypertension.


Condition Intervention
Diabetes Mellitus
Essential Hypertension
 Drug: Fosinopril
Drug: Metformin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by China-Japan Friendship Hospital:

Primary Outcome Measures:
  • Blood pressure measurement [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 140
Study Start Date: May 2006
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Fosinopril group
Fosinopril group received fosinopril, 10mg, once per day.
 Drug: Fosinopril
Fosinopril group received fosinopril, 10mg, once per day.
Experimental: Metformin group
Metformin group was treated with metformin hydrochloride, 500mg, three times per day
 Drug: Metformin
Metformin group was treated with metformin hydrochloride, 500mg, three times per day

  Eligibility

Ages Eligible for Study:   20 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 20 to 65 years of age, regardless of sex
  • duration of hypertension was <5 years
  • overweight or obesity, mild to moderate hypertension, receive no euglycemic agent or antiobesity drug
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Prof. LI Guangwei, China-Japan Friendship Hospital
ClinicalTrials.gov Identifier: NCT01342614     History of Changes
Other Study ID Numbers: MET140
Study First Received: April 26, 2011
Last Updated: May 11, 2011
Health Authority: China:Ethical Committee of the China-Japan friendship Hospital

Keywords provided by China-Japan Friendship Hospital:
Hypertension
Insulin Resistance
Hyperinsulinemia
Metformin
Fosinopril

Additional relevant MeSH terms:
Diabetes Mellitus
Hyperinsulinism
Hypertension
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Metformin
Fosinopril
 Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 16, 2013